Dr Reddy's Laboratories Launches Doxycycline Capsules

Hyderabad: Dr Reddy's Laboratories Ltd. has announced its launch of Doxycycline Capsules, 40 mg in the U.S. market, a therapeutic generic equivalent of ORACEA (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA).

About Doxycycline

Doxycycline is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Inflammatory lesions, including papules and pustules, are common symptoms of rosacea. These lesions manifest as raised, red bumps (papules) and pus-filled bumps (pustules) on the skin, typically on the face. They are often accompanied by redness, swelling, and sensitivity in the affected areas.

Product Details

Dr. Reddy’s Doxycycline Capsules, 40 mg, are supplied in bottle counts of 30. Each capsule contains:

• 26 mg immediate-release pellets
• 14 mg delayed-release pellets equivalent to 40 mg of anhydrous doxycycline, USP

ORACEA is a trademark of Galderma Holdings, S.A.

About Dr Reddy's Laboratories

Established in 1984, Dr Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. Dr Reddys offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddys major markets include:

• USA
• India
• Russia & CIS countries
• China
• Brazil
• Europe

Related News

• Read also: Nestle India, Dr Reddy's to form JV to bring nutraceutical brands to consumers in India, other agreed territories
• Read also: Dr Reddy's Laboratories gets CDSCO Panel Nod To Import and Market Toripalimab 240mg solution for infusion